GGrantIndex
← Search

Evaluation of GLG-302, a STAT3 Antagon

$395,906N03FY2013CANIH

University Of Alabama At Birmingham, Birmingham AL

Investigators

Abstract

The primary goal of this task order is to determine whether GLG-302 (an inhibitor of STAT3 signaling) has cancer chemopreventive efficacy in preclinical models of breast cancer.

View original record on NIH RePORTER →